



UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE
United States Patent and Trademark Office
Address: COMMISSIONER FOR PATENTS
P.O. Box 1430
Alexandria, Virginia 22313-1430
www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
09/892,345	06/26/2001	Gregory Carlson	7651/1612	3543

7590 11-07/2003
Novartis Corporation
Corporate intellectual Property
One Health Plaza, Bldg. 430
East Hanover, NJ 07936-1080

EXAMINER

SERGEANT, RABON A

ART UNIT	PAPER NUMBER
----------	--------------

1711

DATE MAILED: 11/07/2003

Please find below and/or attached an Office communication concerning this application or proceeding.



UNITED STATES DEPARTMENT OF COMMERCE
Patent and Trademark Office
Address: COMMISSIONER OF PATENTS AND TRADEMARKS
Washington, D.C. 20231

SERIAL NUMBER	FILING DATE	FIRST NAMED APPLICANT	ATTORNEY DOCKET NO.
09/892,345	06/26/2001	Carlson	7651/1612

EXAMINER	
Sergent	
ART UNIT	PAPER NUMBER
1711	110303

DATE MAILED:

Please find below a communication from the **EXAMINER** in charge of this application.

Commissioner of Patents

The reply filed on August 14, 2003 is not fully responsive to the prior Office Action because of the following omission(s) or matter(s): The amendment fails to comply with 37 CFR 1.121, because the claims contain amendments that have not been identified in accordance with the provisions of the rule. An example of noncompliance can be found in claims 3, 4, and 5, where polyalkylene oxide has been improperly amended to alkylene oxide. See 37 CFR 1.111. Since the above-mentioned reply appears to be *bona fide*, applicant is given **ONE (1) MONTH or THIRTY (30) DAYS** from the mailing date of this notice, whichever is longer, within which to supply the omission or correction in order to avoid abandonment. EXTENSIONS OF THIS TIME PERIOD MAY BE GRANTED UNDER 37 CFR 1.136(a).

As a result of applicants' amendment, the following issues have been noted: Within claims 3, 4, and 5, the language, "said at least one alkylene oxide", lacks antecedent basis and within claim 46, isocyanurate and biuret have been misspelled.

Any inquiry concerning this communication should be directed to R. Sergent at telephone number (703) 308-2982.

R. Sergent

November 3, 2003


RABON SERGENT
PRIMARY EXAMINER